A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia

NCT01009931 Phase 2 TERMINATED Results posted

This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.

Details

Lead sponsor	Rutgers, The State University of New Jersey
Phase	Phase 2
Status	TERMINATED
Enrolment	1
Start date	2011-03
Completion	2014-09

Conditions

• Leukemia

Interventions

• 12-O-tetradecanoylphorbol-13-acetate
• Dexamethasone
• Choline magnesium trisalicylate

Primary outcomes

• Response Rate > 20% for 12-O-tetradecanoylphorbol-13- Acetate (TPA)+ Dexamethasone + Choline Magnesium Trisalicylate(Trilisate) — 42 months
• Grade 3 and 4 Non-hematologic Treatment-related Toxicity Rates < 25% — 43 months

Countries

United States